Overexpression of SOCS-2 in advanced stages of chronic myeloid leukemia: Possible inadequacy of a negative feedback mechanism

Blood

Volumn 99, Issue 5, 2002, Pages 1766-1775

  Schultheis, Beate ^a,b   Carapeti Marootian, Melina ^a,b   Hochhaus, Andreas ^a,b   Weißer, Andreas ^a,b   Goldman, John M ^a,b   Melo, Junia V ^a,b,c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; GENE PRODUCT; IMATINIB; PROTEIN TYROSINE KINASE; SUPPRESSOR OF CYTOKINE SIGNALING 2; UNCLASSIFIED DRUG;

ARTICLE; CHRONIC MYELOID LEUKEMIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; ENZYME ACTIVATION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LEUKEMOGENESIS; MALIGNANT TRANSFORMATION; MOLECULAR CLONING; MONONUCLEAR CELL; NEGATIVE FEEDBACK; PRIORITY JOURNAL; TRANSCRIPTION REGULATION; TUMOR CELL LINE;

EID: 0036493796     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.5.1766     Document Type: Article

References (42)

1. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype
2. bcr/abl gene of the Philadelphia chromosome
3. Signal transduction pathways involved in BCR-ABL transformation
4. BCP/ABL induces multiple abnormalities of cyloskeletal function
5. Interferon-alpha restores normal adhesion of chronic myelogenous leukemia hematopoietic progenitors to bone marrow stroma by correcting impaired beta 1 integrin receptor function
6. BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia
7. A family of cytokine-inducible inhibitors of signalling
8. Cloning and functional analysis of new members of STAT induced STAT inhibitor (SSI) family: SSI-2 and SSI-3
9. Cloning and characterization of novel CIS family genes
10. Twenty proteins containing a C-terminal SOCS box form five structural classes
11. Gigantism in mice lacking suppressor of cytokine signalling-2
12. Interaction of human suppressor of cytokine signaling (SOCS)-2 with the insulin-like growth factor-I receptor
13. Insulin-like growth factor 1 inhibits apoptosis using the phosphatidylinositol 3′-kinase and mitogen-activated protein kinase pathways
14. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein
15. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells
16. Changes in the carbohydrate metabolism of mitogenically stimulated human peripheral lymphocytes. 3. Stimulation by tuberculin and allogenic cells
17. Gapped BLAST and PSI-BLAST: A new generation of protein database search programs
18. The I.M.A.G.E Consortium: An integrated molecular analysis of genomes and their expression
19. A temperature sensitive p210 BCR-ABL mutant defines the primary consequences of BCR-ABL tyrosine kinase expression in growth factor dependent cells
20. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
21. An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders
22. Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction
23. Advanced mammalian gene transfer: High titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line
24. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor ST1571: Diverse mechanisms of resistance
25. Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells
26. bcr/ABL-mediated chronic myelogenous leukemia by transduction of primary normal human CD34(+) cells with a BCR/ABL-containing retroviral vector
27. Stimulation of β1-integrin function by epidermal growth factor and heregulin-β has distinct requirements for erbB2 but a similar dependence on phosphoinositide 3-OH kinase
28. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells
29. Expression of the chronic myelogenous leukemia-associated p210bcr/abl oncoprotein in a murine IL-3 dependent myeloid cell line
30. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
31. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
32. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase
33. Increase of bcrabl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression
34. SOCS/CIS protein inhibition of growth hormone-stimulated STAT5 signaling by multiple mechanisms
35. SOCS1 deficiency causes a lymphocyte-dependent perinatal lethality
36. Liver degeneration and lymphoid deficiencies in mice lacking suppressor of cytokine signaling-1
37. Aberrant hematopoiesis in mice with inactivation of the gene encoding SOCS-1
38. Negative regulation of cytokine signaling: STAT-induced STAT inhibitor
39. The SOCS proteins: A new family of negative regulators of signal transduction
40. Dual effects of suppressor of cytokine signaling (SOCS-2) on growth hormone signal transduction
41. Growth hormone preferentially induces the rapid, transient expression of SOCS-3, a novel inhibitor of cytokine receptor signaling
42. A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors